luspatercept:
Luspatercept Therapy. Luspatercept (ACE-536) is the most recently approved agent (in the United States and Europe) for the treatment of adults with transfusion-dependent β-thalassemia.
Luspatercept Therapy. Luspatercept (ACE-536) is the most recently approved agent (in the United States and Europe) for the treatment of adults with transfusion-dependent β-thalassemia.